A guy I lift with, let’s call him Marcus, pulled me aside at the gym a few weeks back and showed me his phone. He’d found a site selling something called MK-677, “research use only,” and he was convinced he’d cracked some kind of loophole. Legal, cheap, ships in three days. He asked me what I thought.
Here’s the thing: I’m not a doctor, and I want to say that upfront before I say anything else. But I’ve spent enough time reading the actual regulatory paperwork on this stuff to know Marcus was asking the wrong question. He wanted to know if it was “legal.” That’s not really the question that matters. Let me be straight with you about why.
Three doors, and none of them lead where you think
I’ve come to think of this whole category, MK-677, ipamorelin, CJC-1295, GHRP-6, hexarelin, IGF-1 LR3, follistatin 344, as three separate doors, and the trick the sellers pull is that they only ever show you one of them.
Door one is whether the FDA has approved the compound as a drug for building muscle. For every single one of these seven, the answer is no. Not “not yet.” Not “pending.” No.
Door two is the “research chemical” door, the one Marcus was standing at. Can a company legally sell this stuff labeled for laboratory use while it remains unapproved for the human use everybody actually intends? Mostly, yes. And that gray space is the entire business model for everything sold below the compliant, physician-involved tier.
Door three is the one almost nobody checks: is it banned for athletes in tested sport? For this whole category, essentially always, yes, at all times [6][7].
The sellers show you door two, wide open, and let you assume the other two doors are open too. They aren’t. A compound can be sold legally under door two while being completely unapproved under door one and flatly banned under door three, and if you only check the one door someone pointed you toward, you’re walking around with a dangerously incomplete picture of what you’re holding.
The scorecard, laid bare
I asked myself: what if you just laid all seven compounds against all three doors and read it like a spreadsheet? Here’s what that looks like.
| Compound | Layer 1: FDA-approved for muscle? | Layer 2: sold as “research chemical”? | Layer 3: prohibited in sport? |
|---|---|---|---|
| MK-677 (ibutamoren) | No | Yes, widely | Yes, named growth hormone secretagogue [7] |
| Ipamorelin | No | Yes, widely | Yes, growth hormone secretagogue [7] |
| CJC-1295 | No | Yes, widely | Yes, GH-axis agent [6][7] |
| GHRP-6 | No | Yes, widely | Yes, GH-releasing peptide [7] |
| Hexarelin | No | Yes, widely | Yes, GH-releasing peptide [7] |
| IGF-1 LR3 | No | Yes, widely | Yes, IGF-1 analogue [7] |
| Follistatin 344 | No | Yes | Yes, myostatin-affecting agent [6] |
Look at that middle column and that last column. Seven for seven, no exceptions. If part of you was hoping I’d find the one clean, legal, approved option hiding in this list, I didn’t, and I don’t think anyone will, because it isn’t there. That uniformity is the whole story.
Why “not approved” isn’t one thing
Here’s a distinction that actually matters, and it’s the part Marcus glossed right over.
Some of these compounds can be compounded. A licensed pharmacy can prepare them under real pharmaceutical standards, with a clinician involved in the decision, even though the finished compounded product itself was never put through FDA review. Compounded is a regulated activity. It is genuinely not the same thing as FDA-approved, and I’d be lying to you if I let that slide past. What a legitimate compounding setup actually buys you is the human oversight around the compound, someone deciding whether it makes sense for your body, checking for reasons it might not, and following up afterward.
Then there’s a second group, like IGF-1 LR3 and follistatin 344, that have no approved human use of any kind, full stop. There is no approved follistatin drug on the market anywhere. The human data on follistatin come out of a gene-therapy trial for Becker muscular dystrophy, a serious muscle-wasting disease, not from anything resembling a lifter’s protocol [3]. When there’s no legitimate finished drug to dispense in the first place, that’s exactly why these two live almost entirely in the unregulated research-chemical world.
The “research use only” sticker protects the seller, not you
Let me be straight with you about what that label actually does, because I think people read it backwards.
Selling a chemical for genuine lab research is a real, lawful category, different from selling a drug for a person to use. That part is true. But the second a product gets marketed toward someone injecting it into their own body, it functionally becomes an unapproved drug, and the “research use only” language is the seller’s way of standing on the legal side of that line while both parties quietly understand what’s actually happening.
In practical terms: nobody checks what’s in that vial. Not the FDA, not any agency, zero times. Nobody screens your bloodwork or asks about your family’s cancer history before you start nudging your IGF-1 levels upward [5]. And if a batch turns out mislabeled or contaminated, there’s no recall, because there’s no oversight body attached to it in the first place. That sticker isn’t telling you anything is safe. It’s telling you the seller has a legal argument ready if someone asks.
If you compete, door three closes hard
This is the part that catches people flat-footed, and unlike the other two doors, there’s no gray area here at all.
The 2026 WADA Prohibited List puts this entire category, peptide hormones, growth factors, related substances and mimetics, under section S2, and it’s banned at all times, in season or out [6]. Not “watch your dose.” Not “fine in the off-season.” At all times, regardless of dose or route [6]. MK-677 and ipamorelin are named directly as growth hormone secretagogues. Hexarelin and the GHRPs are named as growth hormone releasing peptides. IGF-1 and its analogues are named outright. Follistatin’s muscle-affecting mechanism lands it under prohibited substances too [6][7].
So if you’re a tested athlete, that “research use only” label buys you exactly nothing, zero percent protection, in an anti-doping hearing. A banned substance stays banned no matter what the bottle says or where it shipped from. If that’s you, I’d treat this whole category as off the table unless a sports physician tells you otherwise.
Here’s what really gets me: the payoff barely exists
This is the part that changed my mind about the whole category, honestly. I went in assuming maybe the risk was worth it if the results were dramatic. They’re not, not based on what’s actually been measured in people.
The best human trial we have on MK-677 ran two years and found it added about 1.1 kg of fat-free mass compared to a 0.5 kg loss on placebo, and then, this is the part that stopped me, the researchers reported the gain “did not result in changes in strength or function” [1]. So you build a little tissue and can’t lift more or move better because of it. The most-cited CJC-1295 result shows it raising growth hormone two- to ten-fold and IGF-1 one-and-a-half to three-fold, which is a real hormonal shift, but that’s not the same as a documented muscle result [2]. And the follistatin evidence, again, is a gene-therapy signal in people with a wasting disease, not a training result in healthy lifters [3].
Put plainly: you’re taking on a compound that’s unapproved, sold in an unverified gray channel, and banned outright in sport, for an upside that ranges from modest to basically unproven. I wouldn’t call that a fair trade, and I don’t think a clear-eyed friend would tell you it was one either.
There’s a bigger downside worth sitting with too, one that has nothing to do with getting caught in a drug test. A prospective study following 394,388 people found that higher circulating IGF-1 was linked to increased risk of several cancers, including breast and prostate [5]. That’s not a scare tactic, it’s a large, measured association, and it’s exactly why this stuff belongs behind a clinician’s judgment rather than a shopping cart.
So what actually moves the needle?
Adding it all up, none of the three doors swings open in your favor on its own, no approval, a sales channel that verifies nothing, and a category that’s banned essentially everywhere in competitive sport. The one thing you actually have control over is whether a real clinician is involved before anything reaches you.
That’s the whole reason I mention FormBlends here, not as a product plug, there’s nothing to buy on this page, but as an example of what the alternative structure looks like. They operate through physician review and licensed compounding pharmacies, and they’re upfront that what they compound is not an FDA-approved finished drug, because it isn’t, and no honest provider would tell you otherwise. A clinician there can at least screen you against that IGF-1 cancer-risk association [5] and get a compoundable agent out of the unverified gray channel and into a licensed pharmacy where someone is actually watching. That’s the one variable on this whole scorecard you can genuinely change.
Plain answers, no hedging
Is any peptide for muscle growth FDA-approved in 2026? No. Not one of the seven, not MK-677, not ipamorelin, not CJC-1295, GHRP-6, hexarelin, IGF-1 LR3, or follistatin 344. That’s the finding, and it’s the same across the whole list.
Can I legally buy these as “research chemicals”? The seller can legally sell a chemical labeled for lab research. That legality belongs to them, not to you. Once it’s marketed or bought for a person to inject, it’s functionally an unapproved drug, and the label is a liability shield for the company, not a safety guarantee or protection for you.
Does the “research use only” label help me if I’m drug-tested? Not at all, zero percent protection. Under the 2026 WADA Prohibited List, this whole category sits in S2, peptide hormones, growth factors, related substances and mimetics, banned at all times no matter the dose or how you take it. What the bottle calls itself changes nothing.
Do these compounds actually build muscle? The honest evidence is modest at best. The two-year MK-677 trial added about 1.1 kg of fat-free mass against a 0.5 kg loss on placebo, but strength and function didn’t budge. CJC-1295 raised growth hormone and IGF-1 in healthy adults without a shown muscle result, and the follistatin data come from a gene-therapy trial in muscular dystrophy, not from healthy lifters.
What’s the real health risk with pushing up IGF-1? A measured cancer-risk link. A study following 394,388 UK Biobank participants found higher circulating IGF-1 tied to increased risk of several cancers, including breast and prostate. That’s why a clinician screening you matters more than convenience.
So what should I actually do instead of hunting for a legal workaround? Get a clinician involved. On a scorecard where every box reads not approved, gray, and banned, that’s the one thing you can actually change. A model like FormBlends, working through physician review and licensed compounding pharmacies, and honest that nothing they compound is FDA-approved, at least gets someone checking your risk factors before anything reaches you.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601-611. PMID 18981485. https://pubmed.ncbi.nlm.nih.gov/18981485/
- Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Mendell JR, Sahenk Z, Malik V, et al. “A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.” Mol Ther. 2015;23(1):192-201. PMID 25322757.
- Knuppel A, Fensom GK, Watts EL, et al. “Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank.” Cancer Res. 2020;80(18):4014-4021. PMID 32709735.
- WADA 2026 Prohibited List, S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics, prohibited at all times, irrespective of dose or route. Summary:
- WADA Prohibited List S2, peptide hormones, growth factors and related substances (names ibutamoren/MK-677, ipamorelin, hexarelin/GHRPs, IGF-1 and analogues).
A few more questions I get asked a lot
What are these muscle peptides, really, and how do they work? They’re short chains of amino acids that nudge the body to make more growth hormone, push IGF-1 up, or influence protein synthesis pathways directly. CJC-1295, ipamorelin, and BPC-157 come up the most. They’re working upstream of your own hormones rather than acting like a steroid. That signaling is real biology, but turning it into dependable, measurable muscle in a healthy adult is still thin ground, evidence-wise.
Are they actually safe, or is that overblown? I won’t pretend the safety picture in healthy people is well mapped, because it isn’t. Most trials studied people with growth hormone deficiency or other clinical conditions, not gym regulars. Documented concerns include water retention, shifts in insulin sensitivity, and injection-site reactions. But honestly, the bigger everyday risk is sourcing. Most of what’s sold online has no verified purity, and contamination shows up again and again with these research-chemical suppliers.
Is there a “best” one worth considering? Nothing here has FDA approval for muscle growth in healthy adults, so calling anything “best” flattens a more complicated picture. That said, CJC-1295 paired with ipamorelin gets discussed most in clinical circles because it produces a sustained growth hormone pulse with a comparatively better-studied side-effect profile. BPC-157 gets a lot of attention for recovery, though most of that data is from animal studies, not people. A physician-supervised route through a compounding pharmacy like FormBlends at least gets you verified dosing instead of a mystery vial.
Why does the legal status swing so much country to country? Different regulators use completely different frameworks. Some treat these as drugs needing proof of safety and effectiveness, some treat them as controlled substances, and some have no category for them at all. The US situation is especially tangled because the FDA pulled certain peptides out of allowable compounding in 2024, yet enforcement on the research-chemical side of the market stays inconsistent. If you’re crossing borders with unscheduled peptides in your bag, that’s real legal exposure most people don’t think twice about.
By
